A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Bortezomib (Primary) ; Sorafenib
- Indications Malignant melanoma
- Focus Adverse reactions
- 07 Jun 2016 Status changed from active, no longer recruiting to completed.
- 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 29 Nov 2012 Planned end date changed from 1 Sep 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov record.